查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1524249

原代細胞培養市場 - 按細胞類型、組成、應用、最終用戶 - 全球預測

Primary Cell Culture Market - By Cell Type, Component, Application, End-user - Global Forecast
出版日期: | 出版商: Global Market Insights Inc. | 英文 190 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

隨著人們對再生醫學的興趣日益濃厚，全球原代細胞培養市場在 2024 年至 2032 年間的複合年成長率將超過 12.2%。由於再生醫學旨在使用細胞療法修復或替換受損的組織和器官，因此對原代細胞培養物作為真實細胞模型的需求激增。這些培養物使研究人員能夠研究對於開發有效的再生療法至關重要的細胞行為、分化和相互作用。這一趨勢強調了原代細胞培養在推進利用人體修復機制的治療、在解決慢性疾病方面有望取得突破以及透過個人化醫療干預改善患者預後的關鍵作用。

舉個例子，2023年10月，加州再生醫學研究所向南加州大學凱克醫學院捐贈了200萬美元。這筆資金鼓勵他們建立新的 cGMP 實驗室，該實驗室旨在加速細胞和基因療法的早期研究，透過現代技術整合將實驗室發現與臨床應用聯繫起來。

整個原代細胞培養產業根據細胞類型、成分、應用、最終用戶和地區進行細分。

到2032 年，人類細胞領域將佔據大量原代細胞培養市場佔有率。 。與細胞系相比，原代人類細胞可以更準確地代表人類生物學，這使得它們對於研究疾病機制和測試新療法不可或缺。這種精確度對於藥物發現和開發至關重要，研究人員越來越依賴原代細胞來驗證藥物功效和安全性。此外，細胞培養技術的進步，加上生物製藥研究投資的不斷增加，進一步推動了原代細胞培養在應對複雜的醫療保健挑戰方面的採用。

由於其在生物製藥生產和研究中的關鍵作用，到 2032 年，培養基領域將在原代細胞培養市場中實現可觀的複合年成長率。原代細胞培養對於生產疫苗、單株抗體和其他生物製劑至關重要，可促進生物製藥產業的成長。這些文化為擴大生產規模提供了可靠的平台，同時保持產品的一致性和品質。此外，細胞培養基配方和生物加工技術的進步提高了原代細胞生物製藥的效率和產量。這種不斷成長的需求凸顯了它們在滿足全球醫療保健需求和推動治療創新方面的至關重要性。

北美原代細胞培養市場從 2024 年到 2032 年將呈現顯著的複合年成長率。此外，嚴格的監管標準和對品質控制的高度重視推動了原代細胞培養物用於藥物測試和驗證目的。此外，北美先進的醫療基礎設施以及學術界、研究機構和製藥公司之間的重要合作為推進細胞培養技術創造了有利的環境。這些因素共同促進了北美在蓬勃發展的市場擴張中的領先地位。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

  • 產業生態系統分析
  • 產業影響力
    • 成長動力
      • 原代細胞培養產品在體外測試中的使用不斷增加
      • 癌症和其他持續性健康狀況的盛行率不斷上升
      • 基因工程方案不斷進步
      • 增加對功能生物學和研究的資助
    • 產業陷阱與挑戰
      • 與使用原代細胞相關的倫理和監管問題
      • 與原代細胞相關的限制
  • 成長潛力分析
  • 監管環境
  • 波特的分析
  • PESTEL分析

第 4 章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 戰略展望矩陣

第 5 章：市場估計與預測：按電池類型，2021 - 2032 年

  • 主要趨勢
  • 動物細胞
  • 人體細胞

第 6 章：市場估計與預測：按組成部分，2021 - 2032 年

  • 主要趨勢
  • 產品
    • 血球
    • 神經細胞
    • 骨髓
    • 內皮細胞
    • 皮膚細胞
    • 肌肉細胞
    • 其他細胞類型
  • 媒體
  • 試劑和補充劑
    • 細胞解離和細胞附著解決方案
    • 緩衝液和鹽
    • 細胞冷凍介質
    • 血清、生長因子和細胞因子
    • 其他試劑和補充劑

第 7 章：市場估計與預測：按應用分類，2021 - 2032

  • 主要趨勢
  • 藥物篩選和毒性測試
  • 疫苗生產
  • 細胞和基因療法開發
  • 再生醫學
  • 其他應用

第 8 章：市場估計與預測：按最終用戶分類，2021 - 2032 年

  • 主要趨勢
  • 製藥和生物技術公司
  • 研究機構和學術實驗室
  • 合約研究組織 (CRO)
  • 其他最終用戶

第 9 章：市場估計與預測：按地區，2021 - 2032

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 亞太地區其他地區
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 南非
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區

第 10 章：公司簡介

  • BioLamina AB
  • Corning Incorporated
  • Creative Bioarray
  • Cyagen
  • FUJIFILM Wako Pure Chemical Corporation
  • Kosheeka
  • Lifeline Cell Technology,
  • Lonza Bioscience
  • Merck KGaA
  • PELOBIOTECH GmbH
  • PromoCell GmbH
  • STEMCELL Technologies
  • Thermo Fisher Scientific Inc.
簡介目錄
Product Code: 9208

Global Primary Cell Culture Market will demonstrate over 12.2% CAGR between 2024 and 2032, ushered by the rising interest in regenerative medicine. As regenerative medicine aims to repair or replace damaged tissues and organs using cellular therapies, the demand for primary cell cultures as authentic cellular models has surged. These cultures enable researchers to study cell behavior, differentiation, and interactions crucial for developing effective regenerative therapies. This trend underscores the pivotal role of primary cell cultures in advancing treatments that harness the body's repair mechanisms, promising breakthroughs in addressing chronic diseases, and improving patient outcomes through personalized medical interventions.

Quoting an instance, in October 2023, Californias Institute of Regenerative Medicine awarded USD 2 million to USCs Keck School of Medicine. The funding encourages their new cGMP Laboratory, designed to accelerate early-stage research on cell and gene therapies, bridging lab discoveries to clinical applications with modern technology integration.

The overall primary cell culture industry is segmented based on cell type, component, application, end-user, and region.

The human cells segment will capture a substantial primary cell culture market share by 2032. The demand for primary cell culture across the human cells segment is rising due to its critical role in advancing personalized medicine and regenerative therapies. Primary human cells offer a more accurate representation of human biology compared to cell lines, making them indispensable for studying disease mechanisms and testing novel therapeutics. This precision is essential in drug discovery and development, where researchers increasingly rely on primary cells to validate drug efficacy and safety profiles. Moreover, advancements in cell culture techniques, coupled with growing investments in biopharmaceutical research, further drive the adoption of primary cell cultures in addressing complex healthcare challenges.

The media segment will register a considerable CAGR in the primary cell culture market through 2032, owing to its pivotal role in biopharmaceutical production and research. Primary cell cultures are essential for producing vaccines, monoclonal antibodies, and other biologics, boosting growth in the biopharmaceutical industry. These cultures provide a reliable platform for scaling up production while maintaining product consistency and quality. Moreover, advancements in cell culture media formulations and bioprocessing technologies enhance the efficiency and yield of biopharmaceuticals derived from primary cells. This growing demand underscores their critical importance in meeting global healthcare needs and advancing therapeutic innovations.

North America primary cell culture market will exhibit a significant CAGR from 2024 to 2032. One key driver is the regions strong presence in biopharmaceutical research and development, supported by substantial investments in healthcare innovation. Additionally, stringent regulatory standards and a high emphasis on quality control propel the adoption of primary cell cultures for drug testing and validation purposes. Moreover, North America advanced healthcare infrastructure and significant collaborations between academia, research institutes, and pharmaceutical companies foster a conducive environment for advancing cell culture technologies. These factors collectively contribute to North America leadership in thriving market expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising usage of primary cell culture products in in-vitro testing
      • 3.2.1.2 Increasing prevalence of cancer and other persistent health conditions
      • 3.2.1.3 Growing advancement in genetic engineering protocols
      • 3.2.1.4 Increase in funding for functional biology and research
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Ethical and regulatory concerns related to the use of primary cells
      • 3.2.2.2 Limitations associated with primary cells
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Porter's analysis
  • 3.6 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Cell Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Animal cells
  • 5.3 Human cells

Chapter 6 Market Estimates and Forecast, By Component, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Products
    • 6.2.1 Blood cell
    • 6.2.2 Nerve cell
    • 6.2.3 Bone marrow
    • 6.2.4 Endothelial cell
    • 6.2.5 Skin cell
    • 6.2.6 Muscle cell
    • 6.2.7 Other cell types
  • 6.3 Media
  • 6.4 Reagents & supplements
    • 6.4.1 Cell dissociation and cell attachment solutions
    • 6.4.2 Buffers and salts
    • 6.4.3 Cell freezing media
    • 6.4.4 Sera, growth factors & cytokines
    • 6.4.5 Other reagents & supplements

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Drug screening and toxicity testing
  • 7.3 Vaccine production
  • 7.4 Cell & gene therapy development
  • 7.5 Regenerative medicine
  • 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End-User, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Pharmaceutical and biotechnology companies
  • 8.3 Research institutes and academic laboratories
  • 8.4 Contract research organizations (CROs)
  • 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
    • 9.3.7 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
    • 9.4.6 Rest of Asia Pacific
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Rest of Latin America
  • 9.6 Middle East and Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 South Africa
    • 9.6.3 UAE
    • 9.6.4 Rest of Middle East and Africa

Chapter 10 Company Profiles

  • 10.1 BioLamina AB
  • 10.2 Corning Incorporated
  • 10.3 Creative Bioarray
  • 10.4 Cyagen
  • 10.5 FUJIFILM Wako Pure Chemical Corporation
  • 10.6 Kosheeka
  • 10.7 Lifeline Cell Technology,
  • 10.8 Lonza Bioscience
  • 10.9 Merck KGaA
  • 10.10 PELOBIOTECH GmbH
  • 10.11 PromoCell GmbH
  • 10.12 STEMCELL Technologies
  • 10.13 Thermo Fisher Scientific Inc.